Orgenesis Inc. P/B ratio

P/B ratio of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/B ratio growth rates and interactive chart. Measures the relationship between price and book value per share. Book value is the equity or owner's capital that is invested in a business. If a stock has a price of $10 and a book value per share of $10, the ratio is 1. Stock selling below a P/B of 1 can be a bargain, as the market price has declined below the net asset value of the business. It is more applicable to financial companies like banks and insurers, as their assets and liabilities are valued at market and the book value thus more accuraterly represents reality.

Highlights and Quick Summary

Current P/B ratio of Orgenesis Inc. is 2.07 (as of December 30, 2020)
  • P/B ratio for the quarter ending June 29, 2021 was 2.41 (a -5.36% decrease compared to previous quarter)
  • Year-over-year quarterly P/B ratio increased by 87.17%
  • Annual P/B ratio for 2020 was 2.07 (a -83.04% decrease from previous year)
  • Annual P/B ratio for 2019 was 12.2 (a 421.27% increase from previous year)
  • Annual P/B ratio for 2018 was 2.34 (a -22.3% decrease from previous year)
Visit stockrow.com/ORGS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/B ratio of Orgenesis Inc.

Most recent P/B ratioof ORGS including historical data for past 10 years.

Interactive Chart of P/B ratio of Orgenesis Inc.

Orgenesis Inc. P/B ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 2.41 2.54 – – –
2020 2.07 1.29 1.48 0.75 2.07
2019 12.2 6.46 4.06 3.78 12.2
2018 2.34 3.04 4.39 4.37 2.34
2017 – 3.51 6.84 10.29 3.83
2016 4.11 0.0 0.0 0.0 4.11
2015 – – – – 0.0

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
© stockrow.com